Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: Effects on painful physical symptoms of depression
David Pérahia(École Normale Supérieure Paris-Saclay), Alan F. Schatzberg(Stanford University), D. Desaiah(Eli Lilly (United States)), Deborah Quail(Eli Lilly (United Kingdom)), Ángel L. Montejo(Universidad de Salamanca)
Cited by 64
Related Papers
Resting-state connectivity biomarkers define neurophysiological subtypes of depression
|Nature Medicine|2016|2.2k
Major depressive disorder
|Nature Reviews Disease Primers|2016|2.1k
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression
|New England Journal of Medicine|2000|1.3k
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma
|Proceedings of the National Academy of Sciences|2003|826